恶性肿瘤放疗加超声热疗的近期疗效  

Preliminary results of radiotherapy plus ultrasound hyperthermia for malignant tumors

作　　者：王瑾[1] 陈乐[2] 黄小玉[2] 邢燕[2] 文浩[2] 

机构地区：[1]四川大学附属华西医院肿瘤中心放疗科,四川成都610041 [2]四川省肿瘤医院放疗科,四川成都610041

出　　处：《中国癌症杂志》2004年第6期546-548,共3页China Oncology

摘　　要：目的 :研究放疗结合超声热疗治疗恶性肿瘤的疗效及毒副反应。方法 :1997年 1月～ 2 0 0 0年 1月间4 1例经病理证实的局部晚期、复发 /转移或对放射敏感性差的表浅性恶性肿瘤患者接受放疗加超声热疗 ,放疗均采用外照射 ,平均剂量 (6 1± 12 )Gy ,热疗于放疗结束后 30分钟内进行 ,1～ 2次 /周 ,平均加热时间为 (5 2 .4± 6 )分钟 ,平均加热 (4.9± 2 .2 )次。采用方差分析肿瘤消退率与热疗参数的关系 ;Kaplan Meier、Cox回归分析三年局部控制率、生存率和预后因素的影响。结果 :CR、PR、NC间的Tmin、Tmax值差异具有统计学意义。全组肿瘤局部CR为 5 8.5 % ,三年局控率、生存率分别为 13.6 %和 32 .6 9%。Tmin、肿瘤体积、放射剂量对三年局控率有显著性影响 (P <0 .0 5 )。超声热疗配合放疗毒副反应较轻。结论 :Tave、Tmax、Tmin、Tmax等参数可用于反映、评价热疗效果 ,放疗结合超声热疗为治疗晚期表浅性恶性肿瘤的有效方法 ,毒性小 ,值得进一步研究。Purpose:To investigate the therapeutic effect a nd toxicity of radiotherapy plus ultrasound hyperthermia for treatment of malign ant tumors. Methods:41 cases of locally advanced, recurrent or radioresista nt cancer treated from January 1997 to January 2000 were given radiotherapy plus Sonotherm 1000 ultrasound hyperthermia. The mean radiation dose was 61±12 Gy;h yperthermia was administered within 30 minutes following radiotherapy with mean heating time of (52.4±6) minutes at 1-2 times/week. 3-year local control and survival were estimated by Kaplan-Meier method and Log rank test, factors affec ting prognosis were analyzed by Cox regression. The significance of differences between temperatures was tested by one-way ANOVA. Results:There was significant difference between Tmin and Tmax on tumor local response. Tumor complete response was 58.5%, the 3-year local co ntrol and survival were 13.6%% and 32.69% respectively. There is significant cor relation between radiation dose, tumor volume, Tmin and 3-year local control ( P<0.05). Conclusions:Tave, Tmax, Tmin could show and evaluate the efffie acy of hyperthermia. Radiotherapy plus ultrasound hyperthermia were effective fo r superficial malignant tumors. Radiation dose, Tmin, tumor volume were related to tumor control.

关 键 词：放疗 超声热疗 局部疗效 预后因素 

分 类 号：R730.58[医药卫生—肿瘤]